New Today

Principal Scientist - Non-clinical PKPD

• Slough

• £53

• Education And Training

Your new company Want to make an application Make sure your CV is up to date, then read the following job specs carefully before applying. You will be joining a leading global biopharmaceutical company based in Slough who are looking for a Principal...

New Today

Principal Scientist - Non-clinical PKPD

• Slough, Berkshire

• £38 -£53 per hour

Your new company You will be joining a leading global biopharmaceutical company based in Slough who are looking for a Principal Scientist to join their Non-Clinical PK/PD team within Early Clinical Development & Translational Sciences. This contract ...

New Today

Principal Scientist - Non-clinical PKPD

• Slough

• £38 -£53 per hour

Your new company You will be joining a leading global biopharmaceutical company based in Slough who are looking for a Principal Scientist to join their Non-Clinical PK/PD team within Early Clinical Development & Translational Sciences. This contract ...

New Today

Principal Scientist - Non-clinical PKPD

• Slough, Berkshire

• £38 -£53 per hour

• Science

Your new company You will be joining a leading global biopharmaceutical company based in Slough who are looking for a Principal Scientist to join their Non-Clinical PK/PD team within Early Clinical Development & Translational Sciences. This contract ...

New Today

Principal Scientist Non-clinical PKPD

• Slough

• Scientist, Science

This is an opportunity to join a successful biopharmaceutical company, delivering novel solutions to a range of disease areas. Using integrated PKPD, modelling, and DMPK approaches you will drive smarter drug development — from target ID to first in ...

New Yesterday

Principal Scientist Non-clinical PKPD

• Slough

• £68,000 - £80,000 /annum

• Research, Academia & Science

This is an opportunity to join a successful biopharmaceutical company, delivering novel solutions to a range of disease areas. Using integrated PKPD, modelling, and DMPK approaches you will drive smarter drug development — from target ID to fir...